Protein targeting into HIV virions based on HIV-1 VPR fusion molecules
US6468539B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Jan 19, 1999 |
| Grant date | Oct 22, 2002 |
| Priority date | — |
| Expiry date | Jan 19, 2019 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2810/6054
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a Vpr protein, a Vpx protein or fragments thereof which permit the development of chimeric molecules that can be specifically targeted into the mature HIV-1 and HIV-2 virions to affect their structural organization and/or functional integrity, thereby resulting in gene therapy for HIV-1 and HIV-2 infections. The present invention also relates to Vpr/Vpx protein Fragments, p6 protein, p6 protein fragment, or functional derivatives thereof which interfere with the native Vpr/Vpx incorporation into HIV-1 and HIV-2 virions. The present invention also relates to treatment of HIV-1 and HIV-2 infections based on the proteins of the present invention.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.